Alnylam Pharmaceuticals
ALNY | NASDAQ
$159.73
-$5.31 (-3.22%)
At close: Nov 16, 2026, 4:00 PM ET
$160.20
+$0.47 (+0.29%)
After-hours:
Nov 16, 2026, 7:51 PM ET
Alnylam Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Yvonne L. Greenstreet | Chief Executive Officer & Director |
| Bryan Andrew Supran | Chief Legal Officer |
| Jeffrey V. Poulton | Chief Financial Officer & Executive Vice President |
| Joshua Brodsky | Vice President of Investor Relations |
| Kevin Joseph Fitzgerald | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development |
| Melissa McLaughlin | Chief Human Resources Officer |
| Phillip A. Sharp | Co-Founder, Member of the Scientific Advisory Board |
| Piyush Sharma | Chief Ethics & Compliance Officer |
| Pushkal Garg | Executive VP & Chief Research & Development Officer |
| Timothy J. Maines | Chief Technical Operations & Quality Officer |
| Tolga Tanguler | Executive VP & Chief Commercialization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 4 | Filing |
| Sep 22, 2026 | 4 | Filing |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jun 03, 2026 | 4 | Filing |
| Jun 03, 2026 | 4 | Filing |
| Jun 03, 2026 | 3 | Filing |
Alnylam Pharmaceuticals
| Country | United States |
| IPO Date | Jun 1, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,500 |
| CEO | Yvonne L. Greenstreet |
Contact Details
675 West Kendall Street Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | ALNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178670 |
| CUSIP Number | 02043Q107 |
| ISIN Number | US02043Q1076 |
| SIC Code | 2834 |
Recent News
- 8 days ago / businesswire.comAlnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
- 11 days ago / seekingalpha.comBrown Advisory Large-Cap Sustainable Growth Strategy Q3 2026 Holdings Performance
- 12 days ago / businesswire.comAlnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
- 14 days ago / businesswire.comAlnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
- 18 days ago / zacks.comALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
- 19 days ago / seekingalpha.comAlnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
- 19 days ago / marketbeat.comAlnylam Pharmaceuticals Q3 Earnings Call Highlights
- 19 days ago / zacks.comAlnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
- 19 days ago / zacks.comCompared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
- 20 days ago / zacks.comAlnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Add to Watchlist
Select watchlists to add or remove ALNY